Valneva SE

Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

18 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

15 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports H1 2022 Results and Provides Corporate Updates

11 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

08 Aug 2022 16:45:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - July 31, 2022

04 Aug 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine

01 Aug 2022 11:45:00 By Nasdaq GlobeNewswire

European Commission Approves Purchase Agreement Amendment for Valneva’s Inactivated COVID-19 Vaccine

20 Jul 2022 12:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - June 30, 2022

05 Jul 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva SE Declaration of shares and voting rights - Interim status at June 22, 2022

27 Jun 2022 02:30:00 By Nasdaq GlobeNewswire

Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

24 Jun 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

24 Jun 2022 01:05:00 By Nasdaq GlobeNewswire

Valneva and Pfizer Announce Closing of Equity Investment

23 Jun 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva announces resumption of trading of its ordinary shares on Euronext Paris

23 Jun 2022 10:00:00 By Nasdaq GlobeNewswire

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe

23 Jun 2022 09:16:12 By Nasdaq GlobeNewswire

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

20 Jun 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces Settlement Agreement with the UK Government

15 Jun 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001

10 Jun 2022 12:30:00 By Nasdaq GlobeNewswire

Valneva Joins Euronext’s Tech Leaders Index

08 Jun 2022 02:30:00 By Nasdaq GlobeNewswire

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

07 Jun 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference

03 Jun 2022 11:45:00 By Nasdaq GlobeNewswire